Maxim Group analyst Anthony Vendetti maintained a Buy rating on Nuwellis (NUWE – Research Report) yesterday and set a price target of $2.50. The company’s shares opened today at $0.65.
According to TipRanks, Vendetti is a 3-star analyst with an average return of 2.7% and a 35.56% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Cutera, ReShape Lifesciences, and Biolase.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nuwellis with a $2.50 average price target.
See the top stocks recommended by analysts >>
NUWE market cap is currently $6.85M and has a P/E ratio of (0.33).
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Read More on NUWE:
- Analysts Are Bullish on These Technology Stocks: Latch (LTCH), Innovid (CTV)
- CRSP Stock Misses Earnings; Here’s Why Revenue Plunged
- New Buy Rating for Roblox (RBLX), the Technology Giant
- RS GROUP PLC ANNOUNCES ACQUISITION OF RISOUL FOR US$275 MILLION
- HPQ Silicon PUREVAP™ Pilot Plant Testing Process Is Advancing and on Schedule
